Development of a safety index of transarterial chemoembolization for hepatocellular carcinoma to prevent acute liver damage.
BACKGROUND
Transarterial chemoembolization (TACE) is the most effective palliative treatment for hepatocellular carcinoma (HCC), but may cause acute liver damage.


METHODS
One hundred and ninteen patients with unresectable HCCs, undergoing TACE, were studied prospectively. A safety index to prevent acute liver damage was developed by using logistic regression.


RESULTS
Acute liver damage by TACE was not related to the gender or age, but was mostly correlated to Child's classification (beta = 1.89, OR = 6.6, CI: 2.07, 21.01) and the amount of Lipiodol (beta = 0.09, OR = 1.09, CI: 1.02, 1.16) used for the TACE.


CONCLUSIONS
In treatment of a Child's B/C patient by TACE, no more than 20 ml Lipiodol should be used.
Hwang
Jen I
JI
Department of Radiology, Taichung Veterans General Hospital, Taiwan, ROC.
Chow
Wai-Keung
WK
Hung
Siu-Wan
SW
Li
Tsai-Chung
TC
Cheng
Yu-Ping
YP
Ho
Yung-Jen
YJ
Lin
Cheng-Chieh
CC
D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage; D006528:Carcinoma, Hepatocellular / Q000628:therapy*; D016461:Chemoembolization, Therapeutic / Q000009:adverse effects / Q000379:methods / Q000592:standards*; D015251:Epirubicin / Q000008:administration & dosage; D006801:Humans; D007459:Iodized Oil / Q000008:administration & dosage; D017114:Liver Failure, Acute / Q000209:etiology / Q000517:prevention & control*; D008113:Liver Neoplasms / Q000628:therapy*; D016015:Logistic Models; D011446:Prospective Studies
D000903:Antibiotics, Antineoplastic; D015251:Epirubicin; D007459:Iodized Oil